CL2019002155A1 - Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas. - Google Patents

Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas.

Info

Publication number
CL2019002155A1
CL2019002155A1 CL2019002155A CL2019002155A CL2019002155A1 CL 2019002155 A1 CL2019002155 A1 CL 2019002155A1 CL 2019002155 A CL2019002155 A CL 2019002155A CL 2019002155 A CL2019002155 A CL 2019002155A CL 2019002155 A1 CL2019002155 A1 CL 2019002155A1
Authority
CL
Chile
Prior art keywords
fusion proteins
factor
procedures
preparation
fix
Prior art date
Application number
CL2019002155A
Other languages
English (en)
Inventor
Robert T Peters
John Kulman
Der Flier Arjan Van
Zhiqian Liu
David R Light
Ekta Seth Chhabra
Tongyao Liu
Ayman Ismail
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CL2019002155A1 publication Critical patent/CL2019002155A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN PROPORCIONA PROTEÍNAS DE FUSIÓN DEL FACTOR IX (FIX) QUE COMPRENDEN AL MENOS UN RESTO HETERÓLOGO, TAL COMO UN XTEN. LA PRESENTE DESCRIPCIÓN DESCRIBE ADEMÁS MÉTODOS PARA PREPARAR Y UTILIZAR LAS PROTEÍNAS DE FUSIÓN DEL FIX.
CL2019002155A 2017-01-31 2019-07-31 Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas. CL2019002155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762452826P 2017-01-31 2017-01-31

Publications (1)

Publication Number Publication Date
CL2019002155A1 true CL2019002155A1 (es) 2020-02-21

Family

ID=61193175

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002155A CL2019002155A1 (es) 2017-01-31 2019-07-31 Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas.

Country Status (19)

Country Link
US (1) US20210238259A1 (es)
EP (1) EP3576762A1 (es)
JP (1) JP2020505424A (es)
KR (1) KR20190112763A (es)
CN (1) CN110831613A (es)
AR (1) AR110871A1 (es)
AU (1) AU2018215092A1 (es)
BR (1) BR112019015569A2 (es)
CA (1) CA3051862A1 (es)
CL (1) CL2019002155A1 (es)
CR (1) CR20190389A (es)
EA (1) EA201991768A1 (es)
IL (1) IL268234A (es)
MA (1) MA47416A (es)
MX (1) MX2019009063A (es)
PH (1) PH12019501765A1 (es)
SG (1) SG11201906788XA (es)
TW (1) TW201831521A (es)
WO (1) WO2018144623A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
CN113817759B (zh) * 2020-07-10 2023-06-02 南京吉迈生物技术有限公司 修饰的因子ix、组合物、方法及其在基因治疗中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4770999A (en) 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP3045539B2 (ja) 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE236987T1 (de) 1992-11-13 2003-04-15 Idec Pharma Corp Konsensus-kozak-sequenzen zur säugetier- exprimierung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
AU737155B2 (en) 1997-03-14 2001-08-09 Biogen Idec Inc. Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
MXPA04001982A (es) 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
PT2363414T (pt) 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
WO2007021494A2 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
WO2008033413A2 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
CN102026653B (zh) 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
SG189790A1 (en) 2008-04-16 2013-05-31 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
TWI573806B (zh) 2008-04-17 2017-03-11 巴克斯歐塔公司 生物活性胜肽
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
KR101813727B1 (ko) 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
SI2506868T1 (en) 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
PL3552619T3 (pl) 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Polipeptydy czynnika ix i sposoby ich zastosowania
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EA201890423A1 (ru) * 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения

Also Published As

Publication number Publication date
AR110871A1 (es) 2019-05-08
MX2019009063A (es) 2019-10-21
EP3576762A1 (en) 2019-12-11
KR20190112763A (ko) 2019-10-07
EA201991768A1 (ru) 2020-01-22
CA3051862A1 (en) 2018-08-09
US20210238259A1 (en) 2021-08-05
PH12019501765A1 (en) 2020-03-16
AU2018215092A1 (en) 2019-08-29
WO2018144623A1 (en) 2018-08-09
CN110831613A (zh) 2020-02-21
TW201831521A (zh) 2018-09-01
IL268234A (en) 2019-09-26
MA47416A (fr) 2019-12-11
BR112019015569A2 (pt) 2020-03-17
JP2020505424A (ja) 2020-02-20
CR20190389A (es) 2019-11-26
SG11201906788XA (en) 2019-08-27

Similar Documents

Publication Publication Date Title
CL2018000302A1 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
CO2020006900A2 (es) Medios y método para preparar vectores virales y usos de los mismos
CO2019003154A2 (es) Anticuerpos anti-pd-1 y sus usos
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
MX2019007021A (es) Anticuerpos il-11ra.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
BR112017009374A2 (pt) ?composições de ramnolipídeo de baixa viscosidade concentradas?
MX2016003939A (es) Formulaciones de anticuerpos anti-pdl1.
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
MX2016013512A (es) Sistemas y metodos para el uso simultaneo del espectro dentro del espectro usado activamente.
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
MX2017002469A (es) Composiciones de matrices extracelulares.
CL2017001227A1 (es) Ganado lechero híbrido y sistemas para maximizar la ventaja híbrida.
MX2023006415A (es) Anticuerpos, usos y metodos.
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
BR112018001814A2 (pt) unidade móvel de produção de implante
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
CL2019002155A1 (es) Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas.
AR101254A1 (es) Instrumentos quirúrgicos de tomografía de coherencia óptica aumentados y sistemas y métodos para corregir movimientos no deseados de instrumentos quirúrgicos
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2017009180A (es) Biomateriales de nanocelulosa sintetizada bacterialmente y de fases múltiples, y método para producirlos.
BR112018014940A2 (pt) combinação de herbicida